CLIA Guidance Draws Industry Criticism On User Comparability Studies
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking waived status for diagnostic tests should be able to choose a statistically appropriate sample for user comparability tests, according to comments submitted by industry on FDA's March 1 draft guidance on criteria for CLIA waiver applications.